Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.44 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.44 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.44 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116242 | 0.92 | GPR119 (0.49) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4111226 | 0.92 | KMT2A (0.47) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4116057 | 0.92 | USP30 (0.46) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4132596 | 0.92 | CCR5 (0.43) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4109003 | 0.92 | MEN1 (0.50) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4116869 | 0.91 | TGFBR1 (0.44) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4110318 | 0.90 | MEN1 (0.43) | MEN1KMT2AKDM1AGPR119PGR | |
| SCHEMBL4116346 | 0.90 | GPR119 (0.44) | MEN1KMT2AKDM1AGPR119USP30 | |
| SCHEMBL4116013 | 0.89 | GPR119 (0.51) | MEN1KMT2ACACNA1BKDM1AGPR119 | |
| SCHEMBL4110556 | 0.89 | MEN1 (0.46) | MEN1KMT2ACACNB4CACNA1ACACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6867221-B2 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1422219-A1 | CYCLIC AMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-6605620-B1 | Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration | KOWA CO., LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | MEN1 4131/4885KMT2A 293/4885CACNB4 588/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | MEN1 4312/4885KMT2A 2020/4885CACNB4 933/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | MEN1 4312/4885KMT2A 2020/4885CACNB4 933/4885 |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | HRH3, HRH4, CNKSR1 | MEN1 3648/4885KMT2A 2879/4885CACNB4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.